Buscar
Coeptis Therapeutics Holdings Inc
COEPAñadir a la lista de seguimiento
16.400USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
579.55MCap. mercado
PérdidaP/E TTM
Más Datos de Coeptis Therapeutics Holdings Inc Compañía
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Información de Coeptis Therapeutics Holdings Inc
Símbolo de cotizaciónCOEP
Nombre de la empresaCoeptis Therapeutics Holdings Inc
Fecha de salida a bolsaDec 17, 2020
Director ejecutivoMehalick (David)
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
Dirección105 Bradford Road, Suite 420
CiudadWEXFORD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal15090
Teléfono17249346467
Sitio Webhttps://coeptistx.com/
Símbolo de cotizaciónCOEP
Fecha de salida a bolsaDec 17, 2020
Director ejecutivoMehalick (David)
Ejecutivos de Coeptis Therapeutics Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
22.50K
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
8.95K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
22.50K
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
8.95K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Coeptis Therapeutics Holdings Inc?
Los cinco principales accionistas de Coeptis Therapeutics Holdings Inc son: Mr. David Mehalick
¿Cuántas instituciones poseen acciones de Coeptis Therapeutics Holdings Inc (COEP)?
A fecha de 2026Q1, 41 instituciones poseen acciones de Coeptis Therapeutics Holdings Inc, con un valor de mercado combinado de aproximadamente 571.15K, lo que representa el 1.17% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 58739.00.